What To Know
- Their experience in the field will be indispensable to the Company in developing a product that allows neurologists to record brain activity and ablate targeted brain tissue in the same procedure.
- NeuroOne CEO Dave Rosa says, “We are honored to have an opportunity to partner with such distinguished neurosurgeons who I believe will be extremely helpful in accelerating our ablation electrode technology program.
NeuroOne notes the formation of a six-member advisory board, made up of leading neurosurgeons, will assist in the completion of the development of a radiofrequency ablation electrode intended to record and ablate brain tissue linked to causing seizure activity.
The six members that have been appointed to the advisory board are as follows:
- Dr. Daniel Couture, Wake Forest Baptist Health
- Dr. Gerald Grant, Stanford University Medical Center
- Dr. Bob Gross, Emory University
- Dr. Zachary Levine, Holy Cross Health, George Washington University
- Dr. Guy McKhann, New York Presbyterian Hospital, Columbia University
- Dr. Jamie Van Gompel, Mayo Clinic
NeuroOne CEO Dave Rosa says, “We are honored to have an opportunity to partner with such distinguished neurosurgeons who I believe will be extremely helpful in accelerating our ablation electrode technology program. Their experience in the field will be indispensable to the Company in developing a product that allows neurologists to record brain activity and ablate targeted brain tissue in the same procedure. The electrode is also expected to save time, cost and potentially improve outcomes, adding value to both patients and physicians that could benefit from this technology.”